Peter Grogg

Age: 84 — Grogg’s longevity in business leadership is rare. Having founded Bachem at a relatively young age and remained active in governance for over 40 years, he exemplifies the endurance required to build and sustain a specialized industrial enterprise.

Source of Wealth: Biochemicals, Self Made — His fortune was not inherited but built from scratch, starting with a modest capital injection and scaling through technical expertise and market positioning.

Residence: Liestal, Switzerland — A town in the canton of Basel-Landschaft, known for its proximity to the pharmaceutical and chemical industries, reflecting Grogg’s deep roots in the Swiss industrial ecosystem.

Citizenship: Switzerland — Swiss citizenship aligns with his business base and likely influences his tax and regulatory environment, including access to stable financial institutions and legal frameworks for long-term asset holding.

Did You Know: In 1971, Grogg bootstrapped Bachem with 50,000 Swiss Francs — a sum equivalent to roughly $50,000 USD at the time. This underscores the power of niche specialization and patient capital in building billion-dollar enterprises without venture funding or external investors.

Ownership Structure: The majority of his Bachem stake is held through Ingro Finanz AG, a structure that likely provides asset protection, estate planning benefits, and centralized management of his diverse holdings.

Investment Philosophy: Grogg’s portfolio — spanning biochemicals, engineering, biopharma, and hospitality — suggests a strategy of diversification within the Swiss economic landscape, balancing cyclical and defensive assets while maintaining control through majority stakes.

Peter Grogg’s net worth is derived almost entirely from his controlling stake in Bachem Holding AG, a Switzerland-based biochemical company he founded in 1971. As of the latest available data, Grogg holds approximately 58% of Bachem Holding AG, a position that grants him significant influence over corporate strategy, capital allocation, and dividend policy. The majority of this stake is held through Ingro Finanz AG, his personal asset management vehicle, which serves as the primary conduit for his equity ownership and wealth preservation. This structure allows Grogg to maintain control while potentially optimizing tax efficiency and asset protection, common practices among long-term family-controlled enterprises in Switzerland.

Bachem Holding AG specializes in the development and manufacturing of active pharmaceutical ingredients (APIs), particularly peptides, amino acid derivatives, and other complex organic molecules. These are critical components in modern drug development, especially for biologics and specialty pharmaceuticals. The company’s niche focus has allowed it to build deep technical expertise and long-term relationships with global pharmaceutical and biotech clients. As a result, Bachem’s valuation is tied not just to current earnings but to its intellectual property, manufacturing capabilities, and its position in the global supply chain for high-value, low-volume APIs.

While lists Grogg as a billionaire, the exact valuation of his stake is subject to market fluctuations, private company accounting practices, and the lack of public disclosure for privately held shares. Unlike publicly traded companies where market capitalization is transparent, private holdings like Bachem require estimation based on comparable public companies, revenue multiples, and earnings before interest, taxes, depreciation, and amortization (EBITDA). The 58% stake implies that Grogg’s personal wealth is highly concentrated — a common trait among founders who retain control — which increases both potential upside and exposure to company-specific risk.

In addition to Bachem, Grogg holds minority positions in other Swiss companies, including Burkhalter Group (electrical engineering) and Polyphor AG (biopharmaceuticals). These investments diversify his portfolio beyond his core biochemical business, though they are not believed to represent a material portion of his total net worth. He also owns 75% of Sunstar Holding AG, a Swiss hotel chain, which adds a real estate and hospitality component to his asset base. This diversification, while limited, may serve as a hedge against sector-specific downturns or regulatory shifts in the pharmaceutical industry.

It is important to note that Grogg’s net worth is not static. It fluctuates with the performance of Bachem Holding AG, changes in private market valuations, and macroeconomic conditions affecting the Swiss franc and global pharmaceutical demand. Unlike public billionaires whose wealth is marked to market daily, Grogg’s net worth is estimated periodically, often based on financial disclosures, analyst reports, or transactions involving similar private companies. This makes his wealth less volatile in the short term but potentially more opaque in terms of real-time valuation.

Peter Grogg’s wealth accumulation is a textbook case of founder-led, long-term value creation in a specialized industrial sector. His journey began in 1971 when he bootstrapped Bachem Holding AG with just 50,000 Swiss Francs — a modest sum that underscores the self-made nature of his fortune. Over the next five decades, Grogg transformed this small biochemical venture into a globally recognized manufacturer of active pharmaceutical ingredients, particularly peptides and amino acid derivatives. His role as CEO until 2002 and chairman until 2012 allowed him to steer the company through multiple economic cycles, technological shifts, and regulatory environments, all while retaining majority ownership.

The early years of Bachem were likely marked by reinvestment of profits, tight cost controls, and strategic partnerships with pharmaceutical clients. As the company grew, Grogg would have faced decisions about scaling manufacturing capacity, expanding into new chemistries, and potentially acquiring complementary businesses. The fact that he retained a 58% stake through multiple rounds of growth suggests he avoided dilution through external financing, a rare feat in capital-intensive industries. This also implies that Bachem generated sufficient internal cash flow to fund expansion, reducing reliance on debt or equity investors.

By the 2000s, Bachem had established itself as a key player in the peptide API market, serving both large pharmaceutical companies and emerging biotech firms. The global demand for complex molecules, driven by the rise of biologics and personalized medicine, provided tailwinds for Bachem’s growth. Grogg’s decision to step down as CEO in 2002 and transition to chairman in 2012 likely reflected a strategic shift toward governance and oversight, allowing professional management to handle day-to-day operations while he focused on long-term strategy and capital allocation.

His wealth history is also shaped by his investment in Ingro Finanz AG, the asset management firm through which he holds the bulk of his Bachem stake. This structure not only centralizes control but also allows for estate planning, tax optimization, and potential succession management. The fact that Grogg remains chairman of Ingro Finanz AG as of the latest data indicates his continued active role in managing his wealth, even as he has stepped back from operational leadership at Bachem.

Additional wealth-building activities include his 75% ownership of Sunstar Holding AG, a Swiss hotel chain, and minority stakes in Burkhalter Group and Polyphor AG. These investments suggest a deliberate diversification strategy, albeit one that remains anchored in Swiss-based, capital-intensive industries. The hotel chain provides exposure to real estate and hospitality, sectors that can offer stable cash flows and inflation protection, while the electrical engineering and biopharmaceutical holdings add industrial and innovation-driven components to his portfolio.

As of 2025, Grogg is ranked #1141 on the Billionaires list, a testament to the enduring value of his core holding in Bachem. His wealth history is not one of rapid accumulation through IPOs or speculative ventures, but of patient, disciplined growth in a niche yet essential segment of the global pharmaceutical supply chain. This model of wealth creation — rooted in technical expertise, operational excellence, and long-term ownership — is increasingly rare in an era dominated by tech unicorns and venture-backed startups.

Looking ahead, Grogg’s wealth will continue to be influenced by Bachem’s ability to innovate, maintain margins in a competitive API market, and navigate regulatory and geopolitical risks. The aging of the founder and potential succession planning at both Bachem and Ingro Finanz AG may also become factors in future wealth dynamics. However, given the company’s strong market position and Grogg’s continued involvement, his net worth is likely to remain stable or grow, assuming no major disruptions in the pharmaceutical industry or Swiss economy.

Peter Grogg’s financial network intersects with several prominent Swiss business figures. Markus Blocher and Miriam Baumann-Blocher are connected through shared financial assets in DOTTIKON ES HOLDING, suggesting potential overlap in investment strategy or board-level collaboration. Rudolf Maag, linked via Spexis, represents another node in the Swiss biotech and pharmaceutical ecosystem, indicating Grogg’s broader influence in the sector. These relationships may reflect shared interests in Swiss industrial and scientific enterprises, though specific collaborative ventures are not detailed in the provided data. Grogg’s peers operate in similar domains — chemicals, engineering, and biopharma — and often hold controlling stakes in family-owned or closely held firms, mirroring his own model of concentrated, long-term ownership.

Peter Grogg’s early life is not extensively documented in the provided data, but his career trajectory suggests a background rooted in science, engineering, or business — fields that would have equipped him to found and lead a biochemical company in 1971. At the time, the pharmaceutical industry was undergoing significant transformation, with increasing demand for synthetic peptides and complex organic molecules. Grogg’s decision to launch Bachem Holding AG with just 50,000 Swiss Francs indicates a combination of technical knowledge, entrepreneurial drive, and risk tolerance — traits often cultivated through formal education or early professional experience in related industries.

Given that he founded a biochemical company, it is plausible that Grogg had some training in chemistry, biochemistry, or chemical engineering, though this is not explicitly confirmed in the provided information. His ability to build a company from scratch and scale it into a global player over five decades suggests a deep understanding of both the scientific and commercial aspects of the pharmaceutical supply chain. This dual competency — technical expertise combined with business acumen — is a hallmark of successful founders in specialized industrial sectors.

Switzerland’s strong tradition in pharmaceuticals and precision manufacturing likely provided a favorable environment for Grogg’s venture. The country’s stable political climate, skilled workforce, and proximity to major European markets would have supported Bachem’s growth. Grogg’s decision to remain in Switzerland and build his company there, rather than relocating to a more venture-capital-friendly jurisdiction, reflects a long-term, patient approach to wealth creation — one that prioritizes control, stability, and organic growth over rapid scaling or external funding.

While details about his family background, education, or early career are not available in the provided data, Grogg’s self-made status and the modest startup capital suggest he did not inherit wealth or come from a privileged background. Instead, his success appears to be the result of personal initiative, technical skill, and strategic decision-making over a long period. This narrative is consistent with many Swiss industrialists who built their fortunes through niche manufacturing and export-oriented businesses.

As of the latest data, Grogg is 84 years old and continues to hold leadership roles in both Bachem and Ingro Finanz AG, indicating a lifelong commitment to his enterprises. His early life, though undocumented, likely laid the foundation for a career defined by discipline, innovation, and long-term value creation — qualities that have sustained his wealth and influence for over half a century.

Peter Grogg’s path to wealth is a masterclass in founder-led, long-term value creation within a specialized industrial sector. He began his journey in 1971 by founding Bachem Holding AG with just 50,000 Swiss Francs — a sum that underscores the self-made nature of his fortune. Unlike many modern billionaires who rely on venture capital or public markets for funding, Grogg bootstrapped his company, relying on internal cash flow, strategic partnerships, and disciplined reinvestment to fuel growth. This approach allowed him to retain majority ownership — approximately 58% — throughout the company’s evolution, a rare feat in capital-intensive industries where dilution is common.

Bachem’s core business — developing and manufacturing active pharmaceutical ingredients, particularly peptides and amino acid derivatives — positioned it at the intersection of science and commerce. These molecules are essential for modern drug development, especially in biologics and specialty pharmaceuticals, where precision and purity are paramount. Grogg’s technical understanding of the field, combined with his business acumen, enabled Bachem to build deep expertise and long-term relationships with global pharmaceutical clients. This created a moat around the company, protecting it from commoditization and allowing it to command premium pricing for its specialized products.

As CEO until 2002 and chairman until 2012, Grogg guided Bachem through multiple economic cycles, technological shifts, and regulatory changes. His leadership style appears to have emphasized operational excellence, quality control, and customer service — values that are critical in the highly regulated pharmaceutical industry. By stepping down from day-to-day operations in 2002 and transitioning to chairman in 2012, Grogg ensured a smooth succession while maintaining strategic oversight. This phased exit allowed professional management to take the reins while preserving his influence over major decisions.

The majority of Grogg’s ownership in Bachem is held through Ingro Finanz AG, his personal asset management firm. This structure not only centralizes control but also facilitates estate planning, tax optimization, and potential succession management. As chairman of Ingro Finanz AG, Grogg remains actively involved in managing his wealth, even as he has stepped back from operational leadership at Bachem. This dual role — founder, controller, and steward — reflects a long-term perspective that prioritizes sustainability over short-term gains.

In addition to Bachem, Grogg has diversified his portfolio through minority stakes in other Swiss companies, including Burkhalter Group (electrical engineering) and Polyphor AG (biopharmaceuticals). These investments add industrial and innovation-driven components to his asset base, though they are not believed to represent a material portion of his total net worth. His 75% ownership of Sunstar Holding AG, a Swiss hotel chain, introduces a real estate and hospitality element to his portfolio, providing exposure to stable cash flows and inflation protection.

Grogg’s path to wealth is not one of rapid accumulation through IPOs or speculative ventures, but of patient, disciplined growth in a niche yet essential segment of the global pharmaceutical supply chain. His success is rooted in technical expertise, operational excellence, and long-term ownership — qualities that are increasingly rare in an era dominated by tech unicorns and venture-backed startups. As of 2025, he is ranked #1141 on the Billionaires list, a testament to the enduring value of his core holding in Bachem and his ability to build and sustain a globally competitive enterprise over five decades.

Peter Grogg’s empire is anchored in Bachem Holding AG, a Swiss biochemical powerhouse he founded in 1971 with just 50,000 Swiss Francs. The company specializes in high-margin, complex active pharmaceutical ingredients—particularly peptides and amino acid derivatives—serving global pharma giants. Grogg’s 58% stake, held via Ingro Finanz AG, gives him outsized control over strategic direction and capital allocation. Beyond Bachem, his portfolio includes stakes in Burkhalter Group (electrical engineering) and Polyphor AG (biopharma), suggesting a deliberate diversification into adjacent, capital-intensive sectors with regulatory moats. His 75% ownership of Sunstar Holding AG, a Swiss hotel chain, introduces a consumer-facing asset with cyclical exposure, contrasting with the more stable, B2B pharma model. This structure reveals a hybrid empire: deeply rooted in science-driven manufacturing, yet branching into infrastructure and hospitality, creating both resilience and complexity.

Grogg’s leadership style is defined by long-term stewardship and operational discipline. He led Bachem as CEO for over three decades, transitioning to chairman and then honorary chairman—a rare trajectory that signals institutional continuity. His hands-on founding role and continued board presence suggest a preference for direct oversight, even in retirement. The fact that he retains majority control through Ingro Finanz AG implies a centralized governance model, where strategic decisions likely reflect his personal risk appetite and vision. This style has fostered stability but may also create succession bottlenecks. His leadership is not flashy; it’s rooted in technical mastery, capital efficiency, and a deep understanding of the biochemical value chain—traits that have allowed Bachem to thrive in a highly regulated, R&D-intensive industry.

Capital allocation under Grogg has been conservative yet strategic. The bulk of his wealth is concentrated in Bachem, a company that generates steady cash flow from long-term contracts with global pharmaceutical firms. His use of Ingro Finanz AG as a holding vehicle allows for tax-efficient reinvestment and cross-asset diversification. Investments in Burkhalter and Polyphor suggest a focus on Swiss industrial and biotech sectors with high barriers to entry. The 75% stake in Sunstar Holding AG indicates a willingness to deploy capital into non-core, asset-heavy businesses—possibly as a hedge against pharma volatility or as a legacy asset. There’s no evidence of aggressive M&A or leveraged buyouts; instead, Grogg appears to favor organic growth, minority stakes, and long-term asset accumulation. This approach minimizes financial risk but may limit scale in fast-moving markets.

Grogg’s empire faces several latent risks. First, concentration risk: over 50% of his net worth is tied to Bachem, a company exposed to global regulatory shifts, supply chain disruptions, and pricing pressure from generic manufacturers. Second, governance risk: as majority shareholder and honorary chairman, Grogg’s influence may stifle board independence or delay necessary leadership transitions. Third, geopolitical risk: while Switzerland offers political stability, Bachem’s global client base exposes it to trade tensions, export controls, and IP disputes—particularly in the U.S. and China. Fourth, reputational risk: as a private figure with minimal public commentary, any scandal—whether environmental, labor-related, or ethical—could damage trust without a robust PR infrastructure. Finally, succession risk: at 84, Grogg’s continued control raises questions about continuity, especially if family or trusted lieutenants lack the technical or managerial depth to sustain the empire.

Public records show no significant philanthropic activity tied to Peter Grogg. Unlike many billionaires who establish foundations or pledge Giving Pledge commitments, Grogg’s profile remains strictly commercial. This absence may reflect personal preference, Swiss cultural norms around privacy, or a strategic choice to reinvest capital into the business. However, it also leaves him exposed to reputational risk in an era where ESG and social impact are increasingly tied to corporate legitimacy. The lack of visible philanthropy could be interpreted as indifference to societal contribution—or as a sign of hyper-focus on operational excellence. Either way, it represents a gap in legacy-building that may become more pronounced as generational wealth transfer approaches.

Grogg’s political influence is indirect but structurally embedded. As a major Swiss industrialist with stakes in pharma, engineering, and hospitality, he wields economic clout that can shape policy through industry associations, lobbying, and quiet dialogue with regulators. Switzerland’s consensus-driven political system allows business leaders like Grogg to influence outcomes without overt partisanship. His connections to figures like Markus Blocher and Miriam Baumann-Blocher—linked via DOTTIKON ES HOLDING—suggest a network of financial and political capital. However, Grogg himself avoids public political engagement, preferring to operate behind the scenes. This low-profile approach reduces controversy but may limit his ability to advocate for industry-specific reforms, especially as global pharma regulation intensifies.

Peter Grogg’s legacy is one of quiet, technical mastery and enduring institutional building. He transformed a modest startup into a global leader in peptide manufacturing—a niche but critical segment of the pharmaceutical supply chain. His longevity as CEO and chairman, coupled with his continued ownership, underscores a commitment to stewardship over exit. The empire he built is not flashy, but it is durable: rooted in science, protected by regulatory complexity, and diversified across Swiss industrial sectors. His legacy will be measured not in headlines, but in the continued operation of Bachem, the stability of his holdings, and the success of his succession plan. If his heirs or successors can maintain the same discipline, Grogg’s name will remain synonymous with Swiss industrial excellence for decades.

• Profile: Peter Grogg (
• Bachem Holding AG Corporate Website
• Ingro Finanz AG Public Filings
• Swiss Commercial Register for Sunstar Holding AG